H-Index
75
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
21%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 1643-3750

Get your full text copy in PDF

Meta-Analysis of Ubiquilin1 Gene Polymorphism and Alzheimer’s Disease Risk

Tianpeng Zhang, Yingying Jia

(Department of Integrated TCM & Western Medicine, People’s Hospital, Hegang City, Heilongjiang, China (mainland))

Med Sci Monit 2014; 20:2250-2255

DOI: 10.12659/MSM.891030


Background: Some studies have evaluated the association between the Ubiquilin 1 (UBQLN1) gene UBQ-8i polymorphism and Alzheimer’s disease (AD). However, the results remain uncertain. We carried out a meta-analysis to derive a more comprehensive estimation of this association.
Material and Methods: Case-control studies were identified by searching databases of PubMed, EMBASE, Web of Science, CNKI, CBM, Wanfang, and VIP. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association.
Results: The UBQ-8i polymorphism was significantly associated with an increased AD risk (OR=1.15; 95%CI 1.05–1.25; P=0.002). The combination of adjusted ORs also found UBQ-8i polymorphism was significantly associated with AD risk (OR=1.15; 95%CI 1.02–1.30; P=0.02). When stratified by APOE ε4 status, both APOE ε4 carriers and APOE non-ε4 carriers with UBQ-8i polymorphism had significantly increased AD risk (OR=1.28; 95%CI 1.05–1.56; P=0.01 and OR=1.25; 95%CI 1.04–1.50; P=0.02). In the subgroup analysis according to age, UBQ-8i polymorphism was significantly associated with LOAD risk (OR=1.17; 95%CI 1.05–1.31; P=0.005), but not with EOAD risk (OR=1.12; 95%CI 0.95–1.31; P=0.17).
Conclusions: These results suggest that the UBQ-8i polymorphism is associated with AD risk.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree